Skip to Content

Guardant Health Inc GH

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Liquid Biopsy Creates Large Opportunities for Testmakers, Including Potential First Mover Illumina

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

The nascent liquid biopsy market may expand rapidly in the next five to 10 years, and one area of expansion--early cancer detection--could significantly change how cancer is treated. We believe liquid biopsies (a noninvasive method of analyzing tumors using fluids such as blood) may induce a paradigm shift in when cancer is detected and then treated, enabling earlier-stage treatments, where survival rates are higher and treatment costs per patient are lower. In general, a host of incentives for end users, practitioners, and payers could enable the widespread adoption of these tests, and we estimate the liquid biopsy market for early cancer detection could eventually exceed $70 billion in the U.S. alone, with global demand expanding the opportunity even further.
 
We cover three possible leaders in liquid biopsy for early cancer detection--narrow-moat Illumina, no-moat Exact Sciences, and no-moat Guardant Health. Based on our assessment of their valuations, we think the market is exuberant about liquid biopsy, so investors focused on value may have to pick and choose their entry points. Illumina, through its pending acquisition of Grail, could become the first mover and long-term leader in pan-cancer biopsies (for multiple cancers in one test). After further research into Illumina's opportunities with the Grail acquisition, which is scheduled to close in mid-2021, we recently increased our fair value estimate to $343 per share from $285. In our base scenario, we assume that liquid biopsy for the early detection of cancer succeeds with Illumina and its liquid biopsy peers, cumulatively reaching about $12 billion of annual sales in pan-cancer by the end of our 10-year forecast, and we assume that Illumina accounts for over half of that revenue potential with its first-mover and technology advantages. With Grail, we think Illumina's EPS growth can accelerate from the midteens in the next couple of years to over 40% compounded annually during the five years ended in 2027.

Read Full Analysis

Company Profile

Business Description

Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Lunar-1, for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.

Contact
505 Penobscot Drive
Redwood City, CA, 94063
T +1 855 698-8887
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type Speculative Growth
Employees 622